PROF (Profound Medical) NonCurrent Deferred Revenue: $0.44 Mil (As of Mar. 2026)


PROF Profound Medical Corp PROF
73 GF Score
Price $7.19
GF Value $14.28
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Profound Medical NonCurrent Deferred Revenue?

Profound Medical PROF -1.98% 73 NonCurrent Deferred Revenue is $0.44 Mil as of Mar. 2026. GuruFocus rates PROF with a GF Score™ of 73/100 and a GF Value™ of $14.28 (Possible Value Trap). The stock has 1 warning sign investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Profound Medical's non-current deferred revenue for the quarter that ended in Mar. 2026 was $0.44 Mil.

Profound Medical NonCurrent Deferred Revenue Related Terms

Profound Medical NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Profound Medical's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Profound Medical NonCurrent Deferred Revenue Chart

Profound Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.76 0.73 0.05 0.39

Profound Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.07 0.15 0.39 0.44
PROF
73GF Score
Profound Medical Corp PROF
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0.44 Mil mean?
Profound Medical (PROF) has a NonCurrent Deferred Revenue of $0.44 Mil as of Mar. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Profound Medical and its competitors.
Is Profound Medical's NonCurrent Deferred Revenue too high?
Profound Medical's current NonCurrent Deferred Revenue is $0.44 Mil. Overall, Profound Medical has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's NonCurrent Deferred Revenue compare to ABT and SYK?
Profound Medical's NonCurrent Deferred Revenue of $0.44 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Medical Devices & Instruments company?
A good NonCurrent Deferred Revenue depends on the Medical Devices & Instruments industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Profound Medical and its competitors. Profound Medical's current NonCurrent Deferred Revenue is $0.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.28, compared to a current price of $7.19 — trading 49.6% below its estimated fair value. The current NonCurrent Deferred Revenue is $0.44 Mil. Profound Medical's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Profound Medical (PROF), the current NonCurrent Deferred Revenue is $0.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Profound Medical (PROF) Overvalued in 2026?

Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued. The current stock price of $7.19 is trading 49.6% below its estimated GF Value™ of $14.28. GuruFocus considers Profound Medical to be Possible Value Trap.

Key valuation signals for PROF:

  • NonCurrent Deferred Revenue: $0.44 Mil
  • GF Value™: $14.28 vs. price of $7.19 (49.6% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Profound Medical Business Description

Other Exchanges PRN:Canada
Address 2400 Skymark Avenue, Unit 6, Mississauga, ON, CAN, L4W 5K5
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
73GF Score

Get the complete analysis for PROF

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.19
Price
$14.28
GF Value